Canopy Growth (quietly) launches CBD consumer line in U.S.
With no fanfare, Canopy Growth (NYSE:CGC) has launched its hemp-derived CBD brand, First & Free, in the 31 U.S. states that allow such sales.
The line includes softgels, oil drops and topical creams.
The FDA issued a statement last month that it cannot conclude that cannabis compounds are safe in human or animal food products.
Canopy’s First & Free website, still in the testing phase, displays a disclaimer saying: “These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.”
Company spokesperson Jordan Sinclair says early signs are “positive” with some orders successfully placed.
Herbalife to open four new training centers in China
Herbalife Nutrition (HLF +1.9%) announces the opening of a new 9,200 sq. ft. training facility in Chengdu, China, the first four planned by the end of next year. The company says it can accommodate up to 600 customers and distributors for training and education on nutrition and healthy meal preparation.
CASI Pharma’s CD19 CAR-T clinical trial applications OK’d in China
The China National Medical Product Administration (NMPA) has approved CASI Pharmaceuticals’ (NASDAQ:CASI) clinical trial applications for CNCT19 (CD19 CAR-T) in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL) submitted by its partner Juventas Cell Therapy Ltd.
The Company expects to start enrolling patients in early 2020.
CASI has previously acquired exclusive worldwide commercial rights to CNCT19 from Juventas.
FDA OKs Roche’s Tecentriq for first-line lung cancer
The FDA approves Roche (OTCQX:RHHBY) unit Genentech’s Tecentriq (atezolizumab), combined with chemo [Celgene’s Abraxane (paclitaxel protein-bound; nab-paclitaxel) and carboplatin], for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer with no EGFR or ALK mutations.
Theravance Bio files for $150M stock sales deal with Cowen
Theravance Biopharma (NASDAQ:TBPH) has filed a prospectus for a mixed shelf offering, including the potential sale of up to $150M of its common stock through Cowen and Company.
